Erythromycin

Generic Name: Erythromycin

Brand Names: Aktipak, Apo-Erythro-S, Benzamycin, E.E.S., Ery, Ery-tab, Erygel, Eryped, Erythro, Erythrocin, Erythrocin Stearate

Drug Type: Small Molecule

Chemical Formula: C_₃₇H_₆₇NO_₁₃

CAS Number: 114-07-8

Unique Ingredient Identifier: 63937KV33D

Background: Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections,...

Indication: Erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria. The indications for erythromycin have been summarized by body system below:

Respiratory infections
...

Associated Conditions: Acne, Acne Vulgaris, Acute Otitis Media caused by Haemophilus Influenzae, Acute pelvic inflammatory disease caused by Neisseria Gonorrheae Infection, Bacterial Infections, Chancroid, Chlamydia Trachomatis, Chlamydial ophthalmia neonatorum, Community Acquired Pneumonia (CAP), Diphtheria, Erythrasma, Gastroparesis, Granuloma Inguinale, Intestinal amebiasis caused by entamoeba histolytica, Legionella Pneumophila Infections, Listeria infection, Lower Respiratory Tract Infection (LRTI), Lymphogranuloma Venereum, Nongonococcal urethritis, Ophthalmia neonatorum (gonococcal), Pertussis, Postoperative Infections, Primary Syphilis, Respiratory Tract Infections (RTI), Skin and skin structure infections, Staphylococcal Skin Infections, Syphilis, Upper Respiratory Tract Infection, Ureaplasma urethritis, Whooping Cough, Inflammatory papular lesions, Mild Acne vulgaris, Moderate Acne vulgaris, Predominant skin comedones, papules and pustules, Prophylaxis of Rheumatic fever, Pustular lesions, Skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes, Superficial ocular infections

Associated Therapies: -

Clinical Trials

Clinical Observations of Pain and Pruritus Induced by Exposure to Allergic Contact Dermatitis Caused by Macrolides

Not yet recruiting

Conditions: Dermatitis, Allergic Contact

Interventions: Drug: Erythromycin
Other: physiological saline
Drug: Azithromycin

First Posted Date: 2024-08-27

Last Posted Date: 2024-08-27

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 30

Registration Number: NCT06574204

PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]

Not Applicable

Not yet recruiting

Conditions: Preterm Birth

Interventions: Drug: Erythromycin
Drug: Amoxicillin and Erythromycin
Drug: Azithromycin

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: University of Melbourne

Target Recruit Count: 100000

Registration Number: NCT06461429

Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF6001 DPI
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-03

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 24

Registration Number: NCT06395610

Locations: 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

Phase 4

Recruiting

Conditions: Pregnancy, High Risk
Preterm Birth
Preterm Premature Rupture of Membrane

Interventions: Drug: Ceftriaxone 1000 MG
Drug: Ampicillin 2 GM Injection
Drug: Amoxicillin 250 MG
Drug: Clarithromycin 500mg
Drug: Metronidazole 500 mg
Drug: Azithromycin
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-29

Lead Sponsor: Ohio State University

Target Recruit Count: 56

Registration Number: NCT06396078

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

Phase 3

Recruiting

Conditions: Premature Rupture of Membrane

Interventions: Drug: Erythromycin
Drug: Azithromycin

First Posted Date: 2024-02-23

Last Posted Date: 2024-06-04

Lead Sponsor: Inova Fairfax Hospital

Target Recruit Count: 140

Registration Number: NCT06273891

Locations: 🇺🇸
Inova Fairfax Medical Campus, Falls Church, Virginia, United States
🇺🇸
Eastern Viriginia Medical School, Norfolk, Virginia, United States